Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis

Rheumatology

Volumn 47, Issue 8, 2008, Pages 1256-1257

  Teichmann, Lino L ^a   Woenckhaus, M ^a   Vogel, C ^a   Salzberger, B ^a   Scholmerich J ^a   Fleck, M ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; C REACTIVE PROTEIN; CIPROFLOXACIN; COTRIMOXAZOLE; LACTATE DEHYDROGENASE; LEFLUNOMIDE; MEROPENEM; METHOTREXATE; PIPERACILLIN; PREDNISOLONE; RITUXIMAB; SULBACTAM; VANCOMYCIN; VORICONAZOLE;

ACINETOBACTER BAUMANNII; ADULT; ANOREXIA; ARTIFICIAL VENTILATION; BLOOD PRESSURE MEASUREMENT; BRONCHOSCOPY; CASE REPORT; CIGARETTE SMOKING; CLINICAL EXAMINATION; DEATH; DISEASE DURATION; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EMPHYSEMA; FEVER; HEART RATE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; INTENSIVE CARE; LETTER; LOW DRUG DOSE; LUNG INFILTRATE; LUNG LAVAGE; LYMPHOCYTE COUNT; MALE; MICROSCOPY; MULTIPLE ORGAN FAILURE; OROPHARYNX CANDIDIASIS; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INTUBATION; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PNEUMONIA, PNEUMOCYSTIS;

EID: 47849109050     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken234     Document Type: Letter

References (10)

1. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:1098-107.
2. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: Associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996;71:5-13.
3. Kaneko Y, Suwa A, Ikeda Y, Hirakata M. Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: Report of two cases and review of the literature. Mod Rheumatol 2006; 16:36-8.
4. Prekates A, Kyprianou T, Paniara O, Roussos C. Pneumocystis carinii pneumonia in a HIV-seronegative patient with untreated rheumatoid arthritis and CD4+ T-lymphocytopenia. Eur Respir J 1997;10:1184-6.
5. US Food and Drug Administrabon. FDA alert: Rituximab (marketed as Rituxan). December 2006.
6. Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307-12.
7. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007;92:139-40.
8. Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006;176:6147-54.
9. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum 2005; 52:501-13.
10. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulosan. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007;123:66-73.